title: Response.
authors.affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (KN, CSF); Division of Gastroenterology, Massachusetts General Hospital, Boston, MA (ATC). kimmie_ng@dfci.harvard.edu.
authors.forename: Kimmie
authors.initials: K
authors.lastname: Ng
authors.affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (KN, CSF); Division of Gastroenterology, Massachusetts General Hospital, Boston, MA (ATC).
authors.forename: Andrew T
authors.initials: AT
authors.lastname: Chan
authors.affiliation: Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA (KN, CSF); Division of Gastroenterology, Massachusetts General Hospital, Boston, MA (ATC).
authors.forename: Charles S
authors.initials: CS
authors.lastname: Fuchs
mesh_terms: D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001241:Aspirin / Q000008:administration & dosage*; D003110:Colonic Neoplasms / Q000473:pathology* / Q000517:prevention & control*; D052246:Cyclooxygenase 2 Inhibitors / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D001241:Aspirin